im, My mantra: don't sit back and relax on this company. You raise a key point that every investor in Ariad should know: constant vigilance and pressure must be applied on Ariad senior management and the BoD to compel them to be responsible wrt shareholders. They act primarily in their own self interest, which has hamstrung the science from succeeding. Nothing has changed yet.
Note, Iclusig was looking at the $7B Gleevec/Sprycel/Tasigna market. Brig was looking at EGFR/ALK/ROS1 'triple threat', EGFR being the real prize. Ariad spent money, with the full guidance and approval of the BoD, as if that would all happen.
Both these programs utterly collapsed. Iclusig will struggle to get to $.4B by 2018, and '113 will settle for ALK, with good revenue, but at a similar fraction of what its potential was thought to be. And 2 years late.
Yet, after Ariad was forced to fire nearly 1/2 the company, they went about hiring again, and now had to fire all those new people. Same BoD, same nonsense business acumen. Paying themselves without a hiccup along the way, even bonusing execs as if it all of the original potential were came true.
Long way to go.
The BoD overpaid themselves and the CEO, they breached their fiduciary responsibilities, they doctored their records and coerced and bought off their accuser...I want THE TRUTH!!!
